SCHEMBL7145357

SCHEMBL7145357

Nc1nc(OCCN2CCOCC2)c(I)c(-c2ccco2)n1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA2A P29274 8/20 0.45
ADORA1 P30542 4/20 0.43
ADORA3 P0DMS8 1/20 0.43
ADORA2B P29275 1/20 0.43
MEN1 O00255 1/20 0.43
KMT2A Q03164 1/20 0.43
BCHE P06276 1/20 0.41
MAOA P21397 1/20 0.41
ACHE P22303 1/20 0.41
MAOB P27338 1/20 0.41
ALDH1A1 P00352 2/20 0.40
LMNA P02545 1/20 0.40
HIF1A Q16665 1/20 0.40
ADCY10 Q96PN6 1/20 0.39
HSP90AA1 P07900 1/20 0.39
HSP90AB1 P08238 1/20 0.39
SIGMAR1 Q99720 1/20 0.38
KDM4E B2RXH2 1/20 0.38
GAA P10253 1/20 0.38
HPGD P15428 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7169211 0.87 ADORA2A (0.45) ADORA2AADORA1ADORA3ADORA2BMEN1
SCHEMBL6441656 0.85 ADORA1 (0.49) ADORA2AADORA1ADORA3ADORA2BMEN1
SCHEMBL7147897 0.78 ADORA2A (0.43) ADORA2AADORA1ADORA3ADORA2B
SCHEMBL7142558 0.77 ADORA2A (0.46) ADORA2AADORA1ADORA2BMEN1KMT2A
SCHEMBL7171290 0.77 ADORA2A (0.51) ADORA2AADORA1ADORA3ADORA2B
SCHEMBL7403108 0.77 ADORA2A (0.41) ADORA2AADORA1ADORA2B
SCHEMBL5046603 0.76 ADORA2A (0.53) ADORA2AADORA1ADORA3ADORA2B
SCHEMBL6445430 0.75 ADORA1 (0.50) ADORA2AADORA1ADORA3ADORA2BMEN1
SCHEMBL7147379 0.74 ADORA2A (0.49) ADORA2AADORA1ADORA3ADORA2BLMNA
SCHEMBL3272076 0.73 ADORA2A (0.67) ADORA2AADORA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6586441-B2 2-Amino-6-benzylsulfanyl-4-thiophen-2-yl-pyridine-3,5-dicarbo -nitrile as an examplary preferred compound; Alzheimer's and Parkinson's diseases; neuroprotectors; schizophrenia, analgesics; anxiolytic agents; respiratory disorders HOFFMAN-LA ROCHE INC. 2003-07-01 US disclosed
EP-1261327-A2 ADENOSINE RECEPTOR MODULATORS F.HOFFMANN-LA ROCHE AG (CH) 2002-12-04 EP disclosed
US-20010027196-A1 Adenosine receptor ligands and their use in the treatment of disease F. HOFFMANN-LA ROCHE AG (CH) 2001-10-04 US disclosed
WO-2001062233-A2 ADENOSINE RECEPTOR MODULATORS F. HOFFMANN LA ROCHE AG (CH) 2001-08-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010027196-A1 Adenosine receptor ligands and their use in the treatment of disease ADORA2A, ADORA2B, ADORA1 ADORA2A 1/4885ADORA1 3/4885ADORA3 6/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.